iShares U.S. Pharmaceuticals ETF

The iShares U.S. Pharmaceuticals ETF (IHE) outperformed the Simplify Health Care ETF (PINK) over the past year, delivering 42.40% returns versus 29.30%. IHE offers lower costs (0.38% expense ratio), higher dividend yield (1.62%), and focuses on established pharmaceutical giants like Eli Lilly and Johnson & Johnson. While PINK provides active mana...

IHE (U.S. Pharmaceuticals ETF) significantly outperformed IXJ (Global Healthcare ETF) over the past year, driven largely by GLP-1 drug success, particularly from Eli Lilly. While IHE's concentrated focus on domestic pharma delivered 39.70% returns, IXJ's broader global healthcare approach provided more diversification but only 10% returns. Both f...

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals, sold 2,959 shares worth ~$82,000 on March 5, 2026. However, this was a routine, pre-planned tax-withholding sale triggered by RSU vesting, not a discretionary sale indicating loss of confidence. Krishnan retains 16,200 unvested RSUs and recently recei...

Eli Lilly commands a dominant position in the GLP-1 weight loss drug market with its blockbuster drugs Mounjaro and Zepbound, but faces significant long-term challenges. The company's stock trades at a lofty 53x P/E ratio, well above industry averages, while GLP-1 drugs now represent over 50% of revenue. Within a decade, patent cliffs and increas...

Pfizer became the first pharmaceutical company to agree to most-favored-nation pricing with the Trump administration, receiving a three-year tariff grace period in exchange for investing in U.S. manufacturing and potentially creating a new direct sales platform.